Hormonal
Once-weekly subcutaneous retatrutide significantly reduces body weight, BMI, and waist circumference in patients with overweight, obesity, and/or type 2 diabetes compared to placebo.
If you have obesity or type 2 diabetes, once-weekly retatrutide injections can lead to significant weight loss (averaging over 10 kg in these studies) and improved blood sugar control compared to no treatment. Be prepared for potential nausea or vomiting, which are common but usually not severe. The benefits are substantial, but the treatment requires adherence to a weekly injection schedule and dose escalation.
Compared with placebo, retatrutide significantly reduced body weight (WMD –10.66 kg; 95 % CI –17.63, – 3.69), BMI (WMD –4.53 kg/m2; 95 % CI –7.51, – 1.55), and waist circumference (WMD –6.61 cm; 95 % CI –13.17, – 0.05).
Why this rating
Based on 3 RCTs with high heterogeneity (I2 > 90% for weight/BMI) and GRADE assessment of 'low-quality' evidence for body weight and BMI.
Source
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Eric Pasqualotto et al. · Metabolism Open · 2024
DOI 10.1016/j.metop.2024.100321
More from this paper
- Retatrutide increases the rate of gastrointestinal adverse events (nausea, vomiting, constipation) and hypersensitivity reactions compared to placebo, but does not significantly increase serious adverse events.Good
- Retatrutide significantly improves glycemic control, including reductions in HbA1c, fasting glucose, and daily mean blood glucose, in patients with obesity and/or type 2 diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →